BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31732918)

  • 1. Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention.
    Mangiacapra F; Bressi E; Colaiori I; Ricottini E; Cavallari I; Capuano M; Viscusi MM; Spoto S; Barbato E; Di Sciascio G
    J Cardiovasc Transl Res; 2020 Aug; 13(4):668-675. PubMed ID: 31732918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy.
    Rubin GA; Kirtane AJ; Chen S; Redfors B; Weisz G; Baber U; Zhang Y; Stuckey TD; Witzenbichler B; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Mehran R; Ali ZA; Ben-Yehuda O; Stone GW
    Catheter Cardiovasc Interv; 2020 Oct; 96(4):793-801. PubMed ID: 31721430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel.
    Xu K; Ye S; Zhang S; Yang M; Zhu T; Kong D; Chen J; Xu L; Li J; Zhu H; Wang F; Yang L; Zhang J; Fan Y; Ying L; Hu X; Zhang X; Chan NC; Li C
    Circ Cardiovasc Interv; 2019 May; 12(5):e007019. PubMed ID: 31018667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients.
    Viscusi MM; Mangiacapra F; Bressi E; Sticchi A; Colaiori I; Capuano M; Ricottini E; Cavallari I; Spoto S; Di Sciascio G; Ussia GP; Grigioni F
    J Cardiovasc Med (Hagerstown); 2022 Feb; 23(2):135-140. PubMed ID: 34545010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
    Breet NJ; de Jong C; Bos WJ; van Werkum JW; Bouman HJ; Kelder JC; Bergmeijer TO; Zijlstra F; Hackeng CM; Ten Berg JM
    Thromb Haemost; 2014 Dec; 112(6):1174-81. PubMed ID: 25231776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
    You J; Li H; Guo W; Li J; Gao L; Wang Y; Geng L; Wang X; Wan Q; Zhang Q
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():598-605. PubMed ID: 31957972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
    Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
    Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention.
    Nusca A; Tuccinardi D; Proscia C; Melfi R; Manfrini S; Nicolucci A; Ceriello A; Pozzilli P; Ussia GP; Grigioni F; Di Sciascio G
    Cardiovasc Diabetol; 2019 Nov; 18(1):147. PubMed ID: 31706305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel.
    Bömicke T; Valina CM; Stratz C; Amann M; Neumann FJ; Hochholzer W
    Thromb Haemost; 2017 Jul; 117(8):1644-1650. PubMed ID: 28382368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.
    Angiolillo DJ; Capodanno D; Danchin N; Simon T; Bergmeijer TO; Ten Berg JM; Sibbing D; Price MJ
    JACC Cardiovasc Interv; 2020 Mar; 13(5):606-617. PubMed ID: 32139218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.
    Kessler T; Wolf B; Eriksson N; Kofink D; Mahmoodi BK; Rai H; Tragante V; Åkerblom A; Becker RC; Bernlochner I; Bopp R; James S; Katus HA; Mayer K; Munz M; Nordio F; O'Donoghue ML; Sager HB; Sibbing D; Solakov L; Storey RF; Wobst J; Asselbergs FW; Byrne RA; Erdmann J; Koenig W; Laugwitz KL; Ten Berg JM; Wallentin L; Kastrati A; Schunkert H
    Cardiovasc Res; 2019 Aug; 115(10):1512-1518. PubMed ID: 30768153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
    Liang J; Wang Z; Shi D; Liu Y; Zhao Y; Han H; Li Y; Liu W; Zhang L; Yang L; Zhou Y
    Angiology; 2015 Apr; 66(4):319-25. PubMed ID: 24913197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.